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Natural vasopressins have been used, with varying success, in attempts to stop bleeding from esophageal
varices for over two decades. Reasonsforlack ofsuccess include(a) failure to induce a sufficiently prolonged
and constant vasoconstrictor effect at the bleeding site, (b) dangerous side-effects, and (c) release of
plasminogen activator induced by the peptides which can lyse any clot as it forms.
In the last decade analogs ofvasopressin have been developed with a prolonged action, usingtwo separate
principles of chemical modification: (I) hormonogens, and (2) blockage of sites of inactivating enzymatic
cleavage (in particular "carba" analogs without a disulfide bridge). These two categories of analog are
compared here: the carba analogs have the advantages of high potency (higher than the parent hormone)
with prolongation, but are also very active on the plasminogen activator release system. The hormonogens
combine prolongation with low potency, but have lost not only a releasing action on plasminogen activator,
but also, by virtue of altered release kinetics, have effectively lost cardiovascular toxicity.
Mechanisms of analog action and receptor interaction are presented, along with initial clinical experi-
ences.
Over 20 years ago an aqueous mixture of vasopressins (VP) was first used
intravenously in an attempt to stem the flow from bleeding esophageal varices [1].
This application of one ofthe manyactions ofVP, i.e., contraction ofsmooth muscle
associated with the bleeding site, followed recognition that the gut is highly sensitive
to VP [2]. Quantitative studies in the rat, using 86Rb [3] to measure both cardiac
output and regional organ flows [4] showed that the highest sensitivity of both
vascular and non-vascular smooth muscle was in the gut and in the estrogenized
uterus [4,5]. Decreases in blood flow and increases inmotility and tone occurred even
at sub-pressor doses, leaving the kidney and liver relatively unaffected until much
larger doses had been given. Other work demonstrated that both large [6] and small
[7] veins in the abdominal cavity were constricted. More recently, it has been shown
that the shutdown of blood flow to the pancreas is the basis of"ADH inhibition of
secretin-induced exocrine pancreatic secretion" [8].
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All rights of reproduction in any form reserved.The spectrum of biological actions of VP is one of the widest of any known
substance, from claims of memory consolidation and known hormone releasing
actions in the CNS to contractile and permeability effects in all peripheral organs
[2,4]. At about the same timethat VP wasfirst being used in cases ofbleedinginto the
gut lumen, it was also recognized as the most potent known "releaser" of plas-
minogen activator [9]-hardly an activity to be desired in a bleeding state.
Because of the complexities of combinations of biologically advantageous and
disadvantageous actions, along with limitations imposed by the short biochemical
and response half-lives ofthe parent hormones, efforts haved been directed over the
past decade to "reshuffle" their advantages and to prolong their actions by synthetic
alteration of the natural cyclic nonapeptide. The present communication deals with
some of the details of these efforts in terms of both mechanism of action and
apparent clinical effects.
THE LONG-ACTING VP ANALOGS-TWO APPROACHES
Two principles of prolonging the action ofoligopeptide hormones have sofarbeen
used: (a) retardation of the degradative action of enzymes which inactivate the
hormones, or (b) utilization of these and/or similar enzymes in order to cleave
inactive synthetic prohormones or hormonogensi thereby releasing the active hor-
mone at a slow rate. We can illustrate this inthe case ofVP byindicatingpreferential
sites of primary cleavage in the sequence formula of the molecule, which causes
immediate inactivation:
1 2 3 4 5 6 7 8 9
Lys (LVP)
NH2-Cys-Tyr-Phe-Gln-Asn-Cys-Pro- -Gly-NH2
I | Arg (AVP)
S S
In order of probable quantitative significance, the inactivating cleavage sites are: (a)
1-2 C-N (aminopeptidase), (b) 8-9 C-N ("carboxamidopeptidase"), (c) 1-6 S-S
(disulfide reductase), (d) 7-8 C-N ("post-Proline cleaving enzyme"), (e) 6-7 C-N
("pressinoicase"). Of these five sites, the first three would account for the vast
majority of inactivated peptide since the first is present intracellularly in all tissues
and the others are in liver and kidney, each of which has a very large blood flow [4].
The fifth site has so far beenlocalized tothe median eminence region ofthemidbrain
[10] so that, while not quantitatively significant, it could still be functionally
important if part of the VP molecule were acting in the midbrain in different areas
than those associated with the parent hormone. Change inthe biological spectrum of
activity-in contrast to prolongation of action-generally involves the side-chains
rather than the backbone of a bioactive peptide.
The classical first approach to prolonging activity is prevention ofaminopeptidase
action by desamination of the N-terminus [11]:
Lys (dLVP)
CH2-CH2-CO-Tyr-Phe-Gln-Asn-Cys-Pro- -Gly-NH2
I- I Arg (dAVP)
S S
Blockage of enzymes operative at sites (b) and (c) can be achieved, for instance, by
replacement of L-Arg by D-Arg, and this is so drastic a steric alteration that the
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desired smooth muscle actions of VP are almost completely eliminated in, for
instance [8-D-Arg]-VP:
NH2-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH2 (DAVP)
S S
Thus, if we combine both of the above in l-desamino{8-D-Arg]-VP (desmopressin,
dDAVP) the resultant molecule has practically no pressor or other smooth muscle
contractile activity, but has very enhanced and prolonged antidiuretic action and
release effects on plasminogen activator (PA) and factor VIII (F-VIII) [27]:
CH2-CH2-CO-Tyr-Phe-Gln-Asn-Cys -Pro-D-Arg-Gly-NH2 (dDAVP)
S S
These properties have made dDAVP the drug of choice in the management of
diabetes insipidus [28] and also ofuse intreating actual orpotential bleedingepisodes
in hemophiliac patients and those with von Willebrand's disease [27].
Finally, site (c) can be stabilized by supplanting the S-S bridge by a thioether
(SCH2 or CH2S) or an ethylene (CH2CH2) bridge (referred to here as monocarba
and dicarba, respectively) [12]. A schematic representation ofamonocarbaanalog of
VP is shown below:
CH2-CO-Tyr-Phe-Gln-Asn-NH-CH-CO-Pro-Arg-Gly-NH2 (dCAVP)
CH2 Y CH2
where Y = CH2S or SCH2 (if Y = CH2CH2, the molecule is dicarba [dCCAVP]).
Except for the case of antidiuresis, where dCCAVP has both high potency and
prolonged action, dicarba analogs have prolonged VP-like actions but low potency
[12,13] so that large doses would be required in therapeutic applications. The
monocarba VP analogs (either at sequence position 1 or 6) however have not only a
prolonged action, but their potency is higher than that of the parent hormone [14].
Physical chemical parameters related to conformation in solution do not reveal any
alteration by monocarba substitution ofthe active stereochemical form ofthe parent
molecule [13].
The second principle for obtaining prolonged action is illustrated by the formula:
X-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2
S S
where X = N-terminal peptide chain extensions, the most useful ofwhich is Gly-Gly-
Gly [15]. Such hormonogens, includingN-glycyl-glycyl-glycyl{8-lysine]-vasopressin
(Glypressin = tGLVP) provide an inefficient approach to prolongingactivity because
during the time interval required for aminopeptidase "activation" by cleavage of
the added N-terminal glycines, other enzymes inactivate by cleavage of the C-
terminal tripeptide (and for this reason it is 8-Lys and not 8-Arg, since in the latter
case inactivation would be even more rapid and efficient[4]). At most only 10%o ofan
injected dose is "activated" to release the effective nonapeptide, LVP. The remainder
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consists of inactive fragments [16]. On the other hand, what is released is a natural
hormone or fragments thereof and the rate-limiting N-terminal cleavage-activation
so alters distribution kinetics that cardiotoxic levels of LVP are not released into the
circulation even at bolus i.v. doses of tGLVP 1,000 times greater than ordinary
therapeutic ones. Thus, the safety factor seems to favor the hormonogen approach.
Experimental data to prove LVP release, and study its kinetics, was obtained in
cats [16] which allowed serial sampling of sufficient blood for parallel estimations of
both plasma antidiuretic activity(rat assay) and "LVP" concentrations by RIA. The
inverted commas about LVP refer to the fact that the Ab for LVP is sensitive to the
C-terminal tripeptide, so that it cannot distinguish between tGLVP and LVP or even
some fragment thereof. The time courses of both parameters suggested that tGLVP
per se disappears from the circulation as rapidly (3-min half-life) as most other
oligopeptide hormones, with asubsequent slow rise in both activities to peak at about
20 min. This was followed by a slow disappearance curve which was hard to
quantitate. When release kinetics are estimated by biological action on the target
organ, response durations vary greatly depending upon the organ and, in the case of
the uterus, very much also on the stage of the estrus cycle. Thus, in man durations
vary from 120 min on gut motility and facial blanching to over 8 h in the just pre-
menstrual uterus after a single bolus dose of about 5 mcg/kg. Since it seems highly
unlikely that injected peptide would still be circulating 8 h after injection of a
hormonogen, the suggestion has been made both for dDAVP and tGLVP that some
sequestration may occur in a "receptor compartment" which protects the peptide
from inactivating enzymes [12,14].
VP AND VP-ANALOG ACTIVITIES OF RELEVANCE TO
GASTROENTEROLOGY
Ever since crude posterior pituitary extracts were available, it has been known that
they induce gut hyperperistalsis involving colic and/ or diarrhea. While this is
invariably labelled as an "undesirable side-effect" of any VP preparation it may well
beclinically useful and desirable forpatients bleeding into the gut lumen, particularly
those with cirrhosis. Acceleration of the passage of blood shortens transit time and
diminishes the nitrogenous substrate that induces hepatic coma.
Of greater importance, however, is the action of VP and its analogs on gut blood
flow. Figure 1 compares LVP and tGLVP in rat experiments [4]. The natural
hormones have the same short actions in reducing gut blood flow as they do in
eliciting general pressor and antidiuretic responses, while the hormonogen produces
much more prolonged blood flow effects. Equipotent doses demonstrate that the
monocarba VP analogs are 10 to 100 times more potent than the hormonogen in
reducing blood flow. Similar results have been obtained with both the rat and the
human uterus, particularly when the latter isjust pre-menstrual [4,17,18] and this has
been the basis of a successful pilot trial of the efficacy of tGLVP in the control of
menorrhagia and metrorrhagia[19]. Thus, ifpotentially toxic vascular actions on the
coronary circulation can be substantially decreased (as in the case of tGLVP) all of
the remaining vasopressin-like hemodynamic response pattern is useful in any
bleeding state. If these vascular effects are combined with hyperperistalsis without
impairment of blood clotting, we have a constellation of changes optimal for the
patient with GI bleeding. Table 1 documents that both in healthy volunteers and in
patients with advanced liver cirrhosis, tGLVP administration does not result in PA
release, whereas LVP has a marked, if short-lived, effect.
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PlIATE 1. The action oftGLVP (4 mg i.v.) in a patient with heavy bleeding from esophageal varices. Photographs at
the same site in the lower esophagus with a fiberoptic endoscope before (lefi) and 20 min after (righl) the tirst tGLVP
injection (cf. [26]).VASOPRESSINS IN GASTROENTEROLOGY
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FIG. 1. Hemodynamic responses inanesthetized rats toinjection (at time0 onthe abscissa) of 10 ng LVP/ 100g body
wt (dashedlines) vs. 100 ng tGLVP/ 100 g body wt (solidlines). The LVP dose wasjust pressor, the larger tGLVP dose
not at all (BP = blood pressure in mm Hg). Ut = total uterine blood flow and GIT = total gut blood flow (measured by
8Rb distribution) in % of pre-injection levels. CO = cardiac output in ml/min/ 200 g body wt. The prolonged responses
in visceral blood flows shown after tGLVP are identical with those observed after 10 ng/ 100 g doses of dCAVP.
TABLE I
PA levels in venous blood 15 min before(-15) peptide infusion, at the start ofinfusion(0) at the end(+15 min) and at 30
and 60 min after the end of the infusion (+45, +75 min, resp.). Propositi: 5 healthy normal volunteers vs. 7 patients with
advanced liver cirrhosis, documented esophageal varices and abnormal liver function tests. Substances compared: LV.P
vs. tGLVP. Note that both controls and cirrhotics responded to LVP with a short-lived rise in PA (Euglobulin Lysis
Time units) while neither group responded to any dose oftGLVP(CashJD, ProwseC, personal communication). Mean
values i SEM presented, * = value significantly higher than the -15 baseline level.
Substance
(Dose, Total) -15 0 +15 +45 +75 min
LVP-10 Isg
Controls (n = 5) 9.1 9.0 27.5* 17.3* 13.3
±1.2 ±0.9 ±1.9 ±1.8 ±1.4
Patients (n = 7) 28.6 22.5 60.7* 36.0 24.6
*14.2 ±11.2 ±15.2 ±11.4 ±9.8
tGLVP-0.75 mg
Controls (n 5) 8.3 8.2 8.8 10.7 11.6
±1.0 ±0.7 ±0.7 ±1. 1 ±0.6
Patients (n = 7) 24.1 19.2 24.6 24.9 24.6
±10.1 ±8.7 ±12.2 ±8.2 ±9.9
tGLVP-2.0 mg
Patients (n = 3) 52.9 48.7 53.4 51.7 51.4
±10.1 ±8.9 ±10.2 ±10.3 ±10.1CORT AND SCHWARTZ
If the principal mechanism of action of a hormonogen is merely to release LVP
slowly, what then are the advantages over slow, controlled administration of LVP i.v.
or i.a.? Intra-arterial infusion from a pump should theoretically have less of a PA
release action than i.v. infusion[9] but it is difficult and time-consuming to place the
catheter so that the perfused area includes the probable bleeding site and the catheter
can be left in place only a limited time, which may not be long enough to ensure
closure of a variceal wall defect. Intravenous drip infusion is hard to control and
carries with it the danger of overdosage and toxicity. Intravenous pump infusion of
low LVP doses could well compete with tGLVP, but only in those centers in which
sufficient personnel could always be devoted to careful monitoring of all variceal
bleeders on an intensive care unit, and those personnel all had the requisite training
and sufficient reliable pumps were at hand. Since, however, conditions prevailing in
some university hospital centers with a low patient load do not prevail for most
patients who arrive bleeding at hospitals for treatment, it would seem at least to the
present authors that building in prolonged action and engineering out-on a kinetic
basis-the more dangerous and lethal of the side-effects on a molecular basis gives
tGLVP definite advantages over LVP. This is particularly so if we consider adminis-
tering one of the two peptides at home or outside of a hospital environment. Finally,
it is not yet clear whether the only difference between tGLVP and LVP is the kinetics
of distribution of the nonapeptide. So far, even low rates of LVP infusion have been
followed by rises in PA plasma levels, while even large doses of bolus injection of
tGLVP have not. This cannot yet be explained, but the difference to the bleeding
patient should be of importance to treatment.
THE CLINICAL USE OF VP-ANALOGS IN GASTROENTEROLOGY
Glypressin has been tested in four gastroenterological situations to date:
Bleeding Esophageal Varices
Hemorrhage from varices remains a very serious problem which neither intrave-
nous nor intra-arterial administration of natural VP has been demonstrated to solve
[20]. The mortality of a large second or third bleed in a decompensated cirrhotic
patient remains between 60 and80o in various reports [21,22]. Careful use of VP or
correct placement of a Blakemore-Sengstaken tube improves results, but both
procedures require great skill and experience for successful use, and these latter
parameters are not available at all clinical establishments-which often results in
long and dangerous transport of actively bleeding patients to specialized centers.
When one looks at the walls of the submucosal varix, particularly near the site of a
hemorrhage, there appears to be little smooth muscle to respond to any VP stimulus
by contraction. In fact, the suggestion has been made on the basis of X-ray and
balloon studies ofexperimental cirrhosis indogs and also in patients [23] that the VP
effect is actually on the smooth muscle of the lower one-third ofthe esophageal wall.
Theoretically, constriction of esophageal smooth muscle may shut off blood flow in
the penetrating vessels connecting the para-esophageal coronary vein with the
submucosal varices (Fig. 2). If this mechanism is valid, it is clear that any pharmaco-
logical effect, to be useful, must be continuous for a sufficiently long period to allow
the defect in the wall to seal, close off, and organize, and this long-acting activity
must not involve an increase inplasma PA levels. Afurthermechanism ofVP action
in variceal bleeding is the documented [7] prolonged and significant decrease in
portal venous pressure inducedparticularlybytGLVP,whichwould be reflected into
the coronary vein. Since VP and tGLVP are both venoconstrictors in the abdominal
610VASOPRESSINS IN GASTROENTEROLOGY 611
A /1-
FIG. 2. Suggested mechanism of action of VP and tGLVP on bleeding from esophageal varices. Left, bleeding
situation with high portal venous pressure reflected in the para-esophageal coronary vein with flow vectors favoring
bleeding from necrotic breakdown defect in varix wall. Right, VP and VP-analog constrict smooth muscle in lowerthird
of the esophagus, thus compressing the penetrating veins connecting the varix with the coronary vein.
cavity, the decrease in portal venous pressure must result from a decreased arterial
inflow into the bed drained by the portal vein (unless, in addition, the portal vein
reacts differently to VP peptides than the other small and large veins in the visceral
bed).
In a recently published preliminary series of heavy variceal bleeders, tGLVP
therapy with a mean treatment duration of 5 days was associated with a 13%
mortality, compared with 67% in the control group which received either no peptide
drug or only intravenous Pitressin. The only other therapeutic measures used
(Blakemore-Sengstaken intubation, blood replacement, frequent bacotracin enemas)
were applied to both the treated(tGLVP) and control groups[7]. The acute effects of
tGLVP have been observed directly by fiberoptic esophagoscopy and sequential
color photographs insuch patients and one caseis so documented in Plate 1 (courtesy
of Dr. A. Thiede, Christian-Albrechts-Universitaet, Kiel, FRG).
Clearly, in variceal bleeders as in peptic ulcer bleeders, more extensiveclinical data
are needed. We still do not know even in the small series already treated whether
tGLVP changed the ultimate prognosis of these patients.
Bleeding Peptic Ulcers, Both Gastric and Duodenal (24)
In the first published series of patients to receive tGLVP, 9 of the 11 gut bleeders
had peptic ulceration with acute onset of heavy bleeding starting from an otherwise
compensated and "normal" baseline state. Most of the cases had X-ray proven
diagnoses before the bleeding episode in question, and many had bled once previ-
ously but had not been subjected to gastric resection. The therapeutic approach was
adapted to the trial-in order to tryto evaluate the effect oftGLVP, the patients were
treated onlywith blood replacement at a rate which allowed them to reach abalanced
state (with respect to Hb and Hct levels) during 1-3 days of close observation in
hospital with no other medication. These balanced states were established at quite
low levels (e.g., about 8-9 g%s of Hb (Fig. 3)) with an unchanged rate oftransfusion
which was then equated to the rate of blood loss from a hypovolemic patient. AtthisCORT AND SCHWARTZ
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FIG. . Responses (BP in mmHg, thin line, Hb levels in gm%,heavylines) of six patients with heavybleeding from
a proven shallow peptic ulcer, treated with tGLVP (GP) at the dosage levels given (GP - 50 =50uAg/kg/day in 3-4
divided doses, GP - 100 = I00Ag/kg/day in 3-4 divided doses) over the period indicated by the arrows. Days = hospital
days. Numbers above abscissa = no. of blood units (= 500 ml) transfused that given day. Large no. in each square is pt.
no. See text and [24].
point tGLVP was administered at a dosage of 50 mcg/kg/day in divided doses every
6-8 h i.v., and blood replacement was either stopped or slowed-it was in no case
continued at the same or a greater rate than before onset of drug therapy. No other
drugs were used. In all patients in this small group, the onset of tGLVP therapy was
associated with a rising curve of Hb, Hct, and rbc levels, as well as of arterial BP.
Stool benzidine tests showed that bleeding had stopped within 2 days after the onset
oftGLVP and all of the patients were discharged in good conditionwithin one week.
Under ordinary conditions, continuous heavy bleeding over 3-4 days would have
been taken as indication for surgical intervention.
In addition to this therapeutic action, later experience has shown that tGLVP may
be useful in rapid prognosis. It seems that the action of tGLVP is useful in treating
blood loss from small vessels inshallow ulcers. Ifthe gastro-duodenal artery has been
eroded, no vasoconstrictor drug can stop the flow and a lack of response to tGLVP
(given in as high a dosage as 3-4 mg q 6-8 h) has been considered as indication for
prompt surgical intervention [26].
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Profuse Mucosal Bleedingfrom Gastritis
Several cases of profuse GI bleeding from endoscopically verified, diffuse hemor-
rhagic gastritis have occurred in patients with no previous symptoms of peptic ulcer,
but who were on high doses of aspirin, butazolidine, etc., for arthritic conditions.
Their response to tGLVP appeared to be both marked and rapid. Bleeding stopped
within 20 min as monitored by direct intragastric observation [24,26].
Control ofProfuse Bleeding During Upper Abdominal
Surgery Related to Liver Cirrhosis
While this application might eventually prove to be generally useful in abdominal
surgery or trauma because of the prolonged arteriolar and venoconstrictor action of
the drug, the action is most marked in portocaval and splenorenal shunt surgery. The
presence of a profuse bed of collateral veins around the liver combined with portal
venous hypertension often results in very profuse small vessel bleeding during the
surgery which is hard to control. One mg i.v. doses of tGLVP have been reported to
result in lessening or stopping of this bleeding within 5 min and these findings could
be correlated with a decrease in portal venous pressure measured bydirect venipunc-
ture [7]. There was no evidence that this method of hemostasis was associated with
any bleeding "rebound."
There is no experience as yet with the action of VP-analogs in bleeding from the
lower bowel. The blood flow effects of the analogs onthe gut in rats was measured in
the entire gut at once and no differentiation was made between different parts. Since
there is a clear clinical response to upper GI bleeding, we know that the pharmaco-
logical action involves the upper gut-onlyfurther experimental and clinical observa-
tion will determine whether the actions are equally valid on the lower bowel as well.
The only human experience with any carba modification of VP (1-desamino-6-
monocarba-AVP) has involved healthy, non-pregnant women volunteers. In these
studies of uterine blood flow and intraluminal pressure tGLVP was shownto be one-
tenth as potent as dCAVP in reducing endometrial and myometrial blood flow and
increasing luminal pressure. tGLVP is an approved drug in some parts ofEurope for
the treatment of menorrhagia and metrorrhagia.
In conclusion, it would appear that structure-activity studies and synthetic
alterations have been successful in reshuffling the broad spectrum of VP activities.
For clinical application the problems have been: (1) to suppress some actions and
leave others either untouched or augmented, and (2) to prolong the duration of
action after single doses in a controlled manner. Of the two basic approaches
presented-hormonogen and monocarba VP analogs-each has some advantages
and some faults. In the present state of the art, monocarba analogs have the
advantages of enhanced potency and prolonged action, whereas hormonogens
combine prolongation of the most desirable actions of VP, suppression of undesir-
able actions on clotting and the myocardium with a high safety factor.
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